Successful T cell immunotherapy for brain cancer requires that the T cells can access tumour tissues, but this has been difficult to achieve. Here we show that, in contrast to inflammatory brain diseases such as multiple sclerosis, where endothelial cells upregulate ICAM1 and VCAM1 to guide the extravasation of pro-inflammatory cells, cancer endothelium downregulates these molecules to evade immune recognition. By contrast, we found that cancer endothelium upregulates activated leukocyte cell adhesion molecule (ALCAM), which allowed us to overcome this immune-evasion mechanism by creating an ALCAM-restricted homing system (HS). We re-engineered the natural ligand of ALCAM, CD6, in a manner that triggers initial anchorage of T cells to ALCAM and conditionally mediates a secondary wave of adhesion by sensitizing T cells to low-level ICAM1 on the cancer endothelium, thereby creating the adhesion forces necessary to capture T cells from the bloodstream. Cytotoxic HS T cells robustly infiltrated brain cancers after intravenous injection and exhibited potent antitumour activity. We have therefore developed a molecule that targets the delivery of T cells to brain cancer.
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During T cell migration across the BBB in multiple sclerosis, endothelial ALCAM co-localizes in lipid rafts with T cell CD6 18, 19 . To investigate whether the observed ALCAM overexpression could enable T cell transmigration through a cancer BBB, we created an in vitro BBB model by sandwiching a polycarbonate membrane between pTECs and pericytes ( Fig. 1e ). Despite ALCAM overexpression (Extended Data Fig. 2c ), the cancer BBB remained impermeable to T cells both at baseline and after conditioning with GBM supernatant or TGFβ (Fig. 1f ). By contrast, conditioning of a normal BBB, in which pTECs were replaced with normal brain endothelial cells, with IL-6 rendered it highly permissive. The fact that cancer BBB was resistant to the effects of pro-inflammatory and tumour stroma-secreted IL6 suggested that ALCAM overexpression alone is insufficient to enable transmigration of T cells, indicating that perhaps the secondary wave of adhesion, well described in multiple sclerosis, is lacking 12 .
We therefore studied the dynamic expression of the principal mediators of the secondary wave on cancer endothelial cells. In contrast to normal brain endothelial cells, we found that pTECs express lower levels of ICAM1 and no VCAM1 at baseline (Fig. 1g , h, Extended Data Fig. 2d-h) . Culturing pTECs in the presence of GBM supernatant, TGFβ or IL-6 further decreased ICAM1 and markedly upregulated ALCAM. As expected, IL6 increased the expression of ICAM1, VCAM1 and ALCAM in normal brain endothelial cells. Notably, we observed this distinct pattern of adhesion molecule expression in the microvasculature of surgically excised GBM (n = 93) and medulloblastoma (n = 25) but not in normal brains (n = 5; Fig. 1i , Extended Data Fig. 1a ).
The reduction of ICAM1 and elimination of VCAM1 under the influence of tumour-derived factors suggested that pTECs have inherent resistance to interactions with T cells, which explained the impermeability of the cancer BBB seen in Fig. 1f .
Engineering T cells to traverse cancer endothelium
ALCAM expression was intensified in cancer endothelial cells; we therefore reasoned that enhanced T cell anchorage to ALCAM could compensate for the reduced expression of ICAM1. As constitutively expressed CD6 on T cells was insufficient to promote effective TEM, we rationally re-engineered CD6, to create a system for guided homing of T cells to brain cancers.
To extract the homing function of CD6, we computationally mapped the ALCAM binding region to extracellular domain 3 (D3) of CD6, in agreement with previous reports 9, 10 (Fig. 2a , Extended Data Fig. 3a-c) . The prototype HS molecule included a D3 exodomain, an IgG1 hinge and a CD6 transmembrane and signalling domains ( Fig. 2b , Extended Data Fig. 3d ). We multimerized the exodomain (creating a trimer (3HS) and a pentamer (5HS)) to study the effect of enhancing the molecule's crosslinking avidity to ALCAM on T cell behaviour ( Fig. 2c , Extended Data Fig. 3e ) and created tail-less HSΔ molecules to study the role of HS signalling (Fig. 2d, Extended Data Fig. 3f ). We detected HS molecules on the surface of human T cells by probing D3 (Extended Data Fig. 3g , h) and confirmed that they bound specifically to ALCAM ( Fig. 2e, Extended Data Fig. 3g ). The molecular interactions of T cells with the endothelium at the transmigratory cup are mediated by podosynaptic CAMs engaging their cognate ligands to initiate TEM 20 . We detected D3-ALCAM heterodimers in HS T cell transmigratory cups; these intensified with D3 multimerization 20 (Fig. 2f , Extended Data Fig. 3i, j) .
Capture of T cells from the bloodstream, rolling along the vessel wall and firm adhesion are key steps before TEM 21 . To study the effect of HS on TEM kinetics, we used microfluidics flow chambers lined by TGFβ-conditioned ALCAM + endothelium and applied 2 dyne cm -2 shear force, akin to that found in tumour capillary vessels (Extended Data Fig. 3k , l, Supplementary Video 1). HS T cells were captured more frequently, rolled more slowly, and stopped more quickly than normal T cells ( Fig. 2g -i, Extended Data Fig. 3m , n). Multimerization of D3 increased the capture and arrest of T cells, while inclusion of a signalling domain maximized this effect independent of the exodomain. Rolling velocities were similar between T cells expressing different versions of HS, probably because rolling is predominantly influenced by selectins, which are expressed similarly on all T cells 22 . Before extravasation, HS T cells were more resistant to mechanical detachment ( Fig. 2J ) than normal T cells and could therefore resist fluctuations in blood flow typical of tumour neovasculature. HS T cells did not engage normal (ALCAM-negative) endothelial cells.
Next, we evaluated the ability of HS to enable T cell transmigration through our BBB model (Fig. 2k ). Resting BBB allowed negligible T cell migration, but induction of ALCAM led to a substantial increase in migration of HS T cells. Multimerization of the exodomain further increased this migration (5HSΔ > 3HSΔ > HSΔ) and a signalling domain maximized migration across constructs. Blocking the D3-ALCAM interaction using soluble ALCAM abrogated migration with all HS T cells, and washing it largely restored the pre-blocking pattern. Molecular interruption of ALCAM expression on pTECs using small interfering RNA (siRNA) and on human umbilical vein endothelial cells (HUVECs) using CRISPR-Cas9 muted their responsiveness to TGFβ (Extended Data Fig. 4a-f ) and reduced the transmigration of HS T cells (MFI) . c, Topographic co-localization of CD31 and ALCAM over vascular segments (15 high-power fields per tumour averaged; representative from n = 3 with similar results). VTR, validation tandem-repeat. d, ALCAM expression in human GBM pTECs (representative of n = 5) and mouse brain tumour endothelium (bEND.3) at baseline and after conditioning. Supe, supernatant. e, BBB model. HBVP, human brain vascular pericytes. f, Transmigration of T cells through BBB model. Data shown as mean ± s.d.; Student's t-test and one-way ANOVA with Tukey's correction. ***P < 0.001; NS, not significant. nBBB, normal BBB. cBBB, cancer BBB. All experiments done using human T cells; validated for three donors in three or more independent experiments. g, h, CAM expression in pTEC#1 (g; n = 5 pTECs) and HBMEC (h) at baseline and after conditioning. i, High-throughput CAM quantification in five normal brains, 93 GBM and 25 medulloblastoma, each examined twice. Each point is an average of MFI acquired from 15 confocal CD31 +gated vascular-patterned high-power fields and segmented by channelspecific intensity thresholding per tumour. g-i, Data shown as mean ± s.d.; ANOVA with Tukey's correction; **P < 0.01, ***P < 0.001. 
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Article reSeArcH (yellow bars in Fig. 2k ). Homotypic ALCAM-ALCAM binding occurs but is decimated by the 50-fold stronger heterotypic ALCAM-CD6 interaction 1 . We found that elimination of T cell ALCAM improved the transmigration of HSΔ (but not of HS) T cells, indicating that the transmigration of HS T cells is largely mediated through heterotypic interactions of HS with endothelial ALCAM 1 (Extended Data Fig. 4g -j). We concluded that enhanced ALCAM anchorage can trigger BBB transmigration of HS T cells. Multimerization of the HS exodomain produced an incremental increase in TEM; however, signalling through the HS endodomain maximized this effect, indicating that other mechanistic downstream events might be involved in enabling transmigration of HS T cells.
HS harnesses the adhesive power of ICAM1-LFA-1 axis
Although the definite functions of CD6 remain unclear, its signalling is thought to be critical for T cell motility and cell-cell contact 11 . CD6 activates the downstream adaptor SH2-domain containing leukocyte protein of 76 kD (SLP-76) in a shared pathway that results in activation of lymphocyte function-associated antigen-1 (LFA-1). Upon activation, LFA-1 undergoes a conformational change that exposes a ligand binding site for ICAM1 [23] [24] [25] . We reasoned that if HS signalling converges on SLP-76, ICAM1 could be brought into play, explaining the functional superiority of HS T cells over HSΔ T cells.
We sequentially interrogated individual mediators downstream of the HS endodomain that could link to integrin modulation. We found substantial co-clustering of SLP-76 with eGFP-tagged HS molecules (HS-eGFP) but not with eGFP-tagged HSΔ-molecules (HSΔ-eGFP) upon crosslinking with ALCAM immobilized on a glass surface ( Fig. 3a ). SLP-76 binds to CD6 in a zeta-chain-associated protein kinase-70 (Zap-70)-dependent manner, and, in contrast to HSΔ and normal T cells, all HS T cells showed higher ZAP-70 phosphorylation after transmigration through the cancer BBB model 26 . HS T cells also recruited cytosolic talin, a high-molecular-weight cytoskeletal protein that unfolds LFA-1 into a high-affinity conformation 27,28 . Indeed, upon transmigration, talin co-aggregated with and unfolded LFA-1 and engaged ICAM1 at transmigratory cups formed by HS T cells moving between and through ALCAM-expressing endothelial cells (Fig. 3b , c, Extended Data Fig. 5a -c). HSΔ T cells did not show these effects.
We functionally confirmed this finding: BIRT 377, an allosteric inhibitor of unfolded LFA-1 29 , substantially reduced the migratory capacity of HS T cells to levels comparable to those of HSΔ T cells, highlighting the contribution of the CD6 signalling endodomain (Fig. 3d ). The effect of BIRT 377 on the migratory capacity of HSΔ T cells and normal T cells was negligible.
Thus, our data confirmed that CD6 signalling culminates in the unfolding of LFA-1 on T cells, enabling HS T cells to engage low-level ICAM1 and providing the deficient secondary wave of adhesion to cancer endothelial cells ( Fig. 3e ).
Cytoskeletal changes mediate adept transmigration
Talin is concentrated at regions of cell-cell contact, and drives the extravasation of T cells through cortical actin polymerization and maturation of focal adhesion complexes mediated by focal adhesion kinase (FAK) and vinculin 30,31 . We used total internal reflection fluorescence (TIRF) and found that upon landing of T cells on ALCAM-coated glass surfaces, actin was induced and co-localized with HS-eGFP but 
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Article reSeArcH not with HSΔ-eGFP on T cells or with normal T cells ( Fig. 4a, b ). Signalling from FAK promotes adhesion maturation of the migrating T cells and mediates the rear retraction of T cells crawling on endothelial cells and their ultimate protrusion and extravasation 32,33 . We found denser actin and FAK after ALCAM interaction in HS T cells than in HSΔ T cells or normal T cells ( Fig. 4c, d ). We also detected membrane ruffling, the formation of a motile cell surface containing a meshwork of newly polymerized actin, and an enrichment of actin-FAK in lamellipodia and invadopodia using structure illuminating microscopy (SIM), which offers higher lateral resolution ( Fig. 4e ).
To quantify these findings in a technically unbiased manner, we performed high-throughput deconvolution microscopy on T cells from three donors at different levels of ALCAM ( Fig. 4f , g). HS T cells expressed more actin and FAK than normal T cells. In addition, actin and FAK co-localized at the surface, enabling protrusion of the podosynaptic structure of the T cells, which is needed for subsequent endothelial invasion. All HS T cells had more podosynaptic lamellipodia and focal adhesions per cell, and a significantly larger area of spread, than normal T cells, meaning that the cytoskeletal rearrangement is well-tensioned to enable T cell migration.
Collectively, subcellular microscopy demonstrated that HS molecules anchor to the actin cytoskeleton and induce maturation of FAK to enable T cell transmigration.
Targeted homing of HS T cells to brain cancer
ALCAM and its binding region on CD6 are highly conserved, with 93-96% homology between human and mouse, enabling us to assess the ability of intravenous HS T cells to overcome the endothelial blockade and home to orthotopic U87-GBM in severe combined immunodeficiency (SCID) mice ( Fig. 5a ). Flow cytometry of tumour-infiltrating lymphocytes (TILs) demonstrated that all HS T cells had superior specific homing capacity compared to normal T cells, and that 5HS T cells had the densest TIL infiltrate ( Fig. 5b , Extended Data Fig. 6a ).
Next, we injected eGFP-firefly-luciferase (eGFP-FFLuc)-labelled T cells intravenously into mice harbouring U87-GBM (adult GBM) and Daoy-MB (paediatric medulloblastoma) orthotopic grafts, and quantified T cell homing using bioluminescence imaging (BLI). HS T cells had a 1-2 log brighter signal than normal T cells in U87-GBM ( Fig. 5c, d ) and Daoy-MB ( Fig. 5e, f) . Analysis of the spatial orientation of T cells to the 3D reconstituted tumour vasculature in tumour explants showed substantially higher HS T cell signals in the intraand perivascular areas compared to normal T cells ( Fig. 5g, h ). Finally, we used a cranial window and video-rate multiphoton microscopy to examine the in vivo dynamics of HS T cell homing to U87-GBM with single-cell resolution ( Fig. 5i , Extended Data Fig. 6b ). Continuous videography of size-matched vasculature showed more rolling 5HS T cells than normal T cells along tumour vessels and achieving firm arrest ( Fig. 5j , k, Supplementary Videos 2-5). Reconstitution of timelapse images in 3D showed more extravasating HS T cells than normal T cells at the tumour vascular bed (Fig. 5l ).
We investigated whether intravenous 5HS T cells invaded normal tissues, but found negligible TILs in the spleen, lungs and kidneys of U87-GBM-bearing mice, at levels no greater than for normal T cells (Extended Data Fig. 7a ). We also observed no T cells or alterations in the histomorphology of normal brain tissue, despite the presence of a heavy HS T cell infiltrate in the tumour (Extended Data Fig. 7b ). 
Anti-tumour activity of cytotoxic HS T cells
Next, we assessed the ability of HS T cells to deliver a therapeutic complex biological agent to brain cancers ( Fig. 6a ). We armed the most successful design, 5HS T cells, with chimaeric antigen receptors (CARs) specific for human epidermal growth factor receptor 2 (HER2), a glioma antigen currently targeted by CAR T cells in several clinical trials 34 (Extended Data Fig. 8a ). Before testing in animals, we confirmed that only HER2-CAR 5HS T cells, but not 5HS T cells or normal T cells, efficiently killed U87-GBM cells in vitro ( Fig. 6b ). Notably, HER2-CAR 5HS T cells did not lyse normal or tumorous human or mouse endothelial cells ( Fig. 6c ) or any other ALCAM-expressing leukocytes (Fig. 6d ). Thus, HS T cells have no cytolytic activity against ALCAM-expressing targets, and cytolysis is distinctly mediated through engagement of HER2 by the CAR molecules. Similar to HER2-CAR T cells, all HER2-CAR HS T cells exhibited a predominantly effector-memory phenotype and comparable exhaustion and proliferation profiles following transwell migration (TWM; Extended Data Fig. 8b-d) .
To test the antitumour efficacy of HER2-CAR 5HS T cells, we established eGFP-FFluc-labelled orthotopic U87-GBM tumours. Unlabelled T cells were injected intravenously, and tumour growth was monitored. HER2-CAR 5HS T cells induced regression of established tumours in all treated animals, in contrast to HER2-CAR T cells, which transiently slowed tumour growth, and normal T cells ( Fig. 6e, f ). HER2-CAR 5HS T cells were more abundant than HER2-CAR T cells and normal T cells in GBM explants ( Fig. 6g , Extended Data Fig. 9a ) but were absent from non-tumour areas of the brain (Extended Data Fig. 9b ). Kaplan-Meier survival analysis showed that mice treated with HER2-CAR 5HS T cells had a median survival exceeding 60 days, compared to 22 and 18 days for animals treated with HER2-CAR T cells and normal T cells, respectively ( Fig. 6h ).
Discussion
The onset of TEM is mediated by waves of engagement of endothelial cell adhesion molecules to their cognate ligands on T cells, signalling by which mediates the adhesion threshold necessary to pull T cells from the bloodstream 35 . In multiple sclerosis, this threshold is reached by ALCAM crosslinking CD6, followed by a secondary wave of interaction with other ubiquitous CAMs, predominantly ICAM1 36 .
We have shown that, similar to inflammatory endothelial cells, cancer endothelial cells overexpress ALCAM, but abrogate T cell homing by downregulating ICAM1. Our results indicate that the interaction between endogenous CD6 on T cells and ALCAM on cancer endothelial cells alone is incapable of mediating T cell transmigration. We thus created HS, a set of engineered ligands, to enhance the transmigration of T cells through cancer endothelial cells. We demonstrate how HS T cells can harness the power of a preexisting pathway (ICAM1-LFA-1), akin to the secondary wave seen in multiple sclerosis 37,38 . This transforms the ineffective T cell-cancer endothelial cell interaction into a permissive inflammatory one. Subsequently, T cells are guided by a chemokine gradient to their tumour target ( Fig. 6I ). It is likely that this chemokine gradient could interact with and influence the process of TEM.
We created HS to be an abstract ligand based on the minimal moiety on CD6 that could heterodimerize with ALCAM. In doing so, we extracted the homing function of CD6 (mediated by D3) and avoided carrying forward its other unwanted functions, which remain mostly unclear 11 . Indeed, when we cloned and expressed the full-length CD6 on human T cells, their transmigration was improved but they were exceedingly activated at baseline and exhibited a rather exhausted phenotype, failing to expand (Extended Data Fig. 10 ). This confirms recent literature describing D1 of CD6 as a mediator for T cell activation 39 . It also underscores the critical role of rational engineering in the design of synthetic molecules to optimally mediate distinct functions, while simultaneously avoiding unwanted ones.
Poor homing of CAR T cells is a major obstacle to effective T cell therapy 40, 41 . We recently established a favourable safety profile of intravenous HER2-CAR T cells in patients with GBM but observed only disease stabilization and partial responses 42 . As an alternate strategy, we and others have reverted to intra-tumoral administration to achieve the bioavailability needed to elicit a more uniform clinical response (NCT02442297); this approach is rather invasive and of limited applicability. At this stage, we ought to seek highly specific refinements to cellular therapeutics, such as the HS platform, if more durable tumour clinical responses are to be achieved.
HS molecules enhance the ability of therapeutic T cells to exert an antitumour activity while maintaining a favourable safety profile. Adaptations to the HS platform as a modular delivery tool could be made to allow complex therapeutic agents to access diseased brain sites. 
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As a negative control, FITC images were rotated by 180° before calculating the MCCs. Cell culture. Primary brain tumour endothelial cells (pTECs). Primary GBM surgical specimens and other primary tumour samples were obtained on a human protocol approved by the Institutional Review Board (IRB) of Baylor College of Medicine, The Houston Methodist Hospital and Texas Children's and Toronto Children's Hospitals, and were stained or processed to isolate patient-derived pTECs. Patients and healthy donors gave consent before the samples were obtained unless these were from publicly available data sets. In brief, the tissues were minced in DMEM (Gibco, Waltham, MA, USA) and digested with 1 mg/ml collagenase and 10 mg/ml DNase (BD Biosciences, San Diego, CA) in DMEM for 30 min at 37 °C with continuous shaking at 180 r.p.m. The tissue suspension was filtered through a mesh screen (200 μm), washed with Dulbecco's phosphate-buffered saline (D-PBS), centrifuged at 1,000g for 10 min at 4 °C and the pellet was re-suspended in DMEM containing 20% BSA. A second digestion was done for 2 h on a shaker at 180 r.p.m. using collagenase and dispase (1 mg/ml) following which the digested layer was separated on 40% percoll gradient and centrifuged at 700g for 10 min. The endothelial cells were taken from the cloudy interphase, washed in D-PBS and grown in brain endothelial cell medium (EBM; Lonza, Basel, Switzerland) supplemented with 20% fetal bovine serum (FBS), bFGF (20 μg/ml), heparin (100 μg/ml) and puromycin (500 μg/ml) on fibronectin (0.4 mg/ml) and collagen (0.1 mg/ml) pre-coated plates.
After 7-10 days, cells were checked for endothelial cell markers CD31, von Willebrand Factor and VE cadherin. They were sorted on the pan-endothelial marker CD31 at the Baylor College of Medicine Flow-cytometry Core. The viable sorted CD31 + propidium iodide (PI)-negative population of isolated GBM endothelial cells was regrown in EBM in fibronectin/collagen-coated flasks and used at passage 1-2 for the experiments. Other primary and established cell lines. Primary GBM cell lines were isolated from surgically excised GBM specimens as described 44 . Human brain microvascular endothelial cells (HBMECs), HBVPs and CD1 + astrocytes were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). Human lung microvascular endothelial cells (HMVEC-Ls) were obtained from Lonza (Basel, Switzerland). Human umbilical cord vascular endothelial cells (HUVECs), human embryonic kidney-293A (HEK293) cells, U87-GBM cell line mouse cerebral microvascular tumour endothelial cells, bEnd.3, and the mouse lymph node vascular endothelial cells 2-H11 were obtained from ATCC (Manassas, VA, USA). BALB/c mouse primary brain microvascular endothelial cells and BALB/c primary mouse lung microvascular endothelial cells (PMVECs) were obtained from Cell Biologics Inc. (Chicago, IL, USA).
Astrocytes and brain endothelial cells were cultured in EBM supplemented with 20% FBS and growth factors using supplement kit EGM-2 BulletKit containing VEGF, ECGS, heparin, EGF, hydrocortisone, l-glutamine (2 mM) and puromycin (4 mg/ml). HEK293 cells, U87-GBM cell lines and primary GBM cell lines processed in our laboratory were maintained in DMEM supplemented with 10% FBS and 2 mM GlutaMAX-I (Gibco). T cells were maintained in T cell medium (250 ml RPMI-1640, 200 ml CLICKS with 10% FCS containing 2 mmol/l GlutaMAX-I).
All cells were cultured in an incubator at 37 °C in a humid atmosphere of 5% CO 2 and passaged at 70% confluency. All endothelial cells were routinely analysed for CD31 and vWF expression by flow cytometry before use. Immunohistochemistry and immunofluorescence. Expression of ALCAM on primary GBM and medulloblastoma tissue sections was detected by immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) slides. Following deparaffinization and rehydration, endogenous peroxidase activity was blocked with 30% H 2 O 2 and antigen retrieval was performed using Dako antigen retrieval solution (BioGenex, Fremont, CA, USA) for 90 min at 90 °C under pressure. Avidin, biotin (BioGenex) and Fc receptor (Innovex Biosciences, Richmond, CA, USA) blocking reagents were applied to the sections before a 4 °C overnight incubation with rabbit anti-human anti-ALCAM (1:100). The sections were developed with HRP conjugated anti-rabbit antibody (1:1,000; Abcam) using DAB as chromogen (BioGenex). All slides were counterstained in Harris haematoxylin, dehydrated and mounted. Images were acquired using an Olympus light microscope. Scoring of CD3 positive DAB signal was analysed using IHC_Profiler plugin in ImageJ. Images were scored by a pathologist blinded to the conditions. Frozen tissue sections were also made from primary GBM surgical specimens at the Baylor College of Medicine pathology core and used for co-staining of CD31 and ALCAM. The slides were fixed with cold acetone/methanol for 15 min, antigen retrieval performed using 1 × citrate buffer (Thermo Fisher Scientific), blocked with human goat serum for an hour and probed with mouse anti-human CHS1 (1:100) and rabbit anti-human ALCAM antibody (1:50) overnight. Slides were then incubated for an hour with secondary goat anti-rabbit Alexa-fluor 488 and goat anti-mouse Alexa Fluor 647, respectively, counterstained with DAPI and mounted. Tissue images were taken using a Zeiss confocal spinning disk microscope (Zeiss, Oberkochen, Germany) at 40× magnification. Flow cytometry for surface expression of brain endothelial CAMs. For expression of CAMs, 1 × 10 6 HBMECs and pTECs were harvested and stained using anti-human ALCAM-PE, anti-human ICAM1-FITC and anti-human VCAM1-FITC. Expression was analysed by flow cytometry at basal levels, after conditioning with IL-6 (100 ng/ml) TNFα (10, 100, 500 ng/ml), TGFβ (1 μg/ml), and GBM supernatant for 6 h. FlowJo data analysis software (FLOWJO, LLC, Ashland) was used for all flow cytometric analyses.
ALCAM expression during basal and pathological conditions was measured on mouse (2-H11, the BALB-C primary brain endothelium bENd.3 and PMVECs) and human endothelial cells (HBMECs, pTECs, HMVEC-Ls, HUVECs) by flow cytometry. For inflammatory conditions, cells were cultured with TNFα, TGFβ, IL-6, IL-1, IFNγ at optimized concentration of 100 ng/ml for 6 h. To simulate tumour environment, endothelial cells were exposed for 6 h to fresh supernatants from GBM cell culture, and collected 24 and 48 h after addition.
Conditioned and normal cells (1 × 10 6 ) were washed in PBS containing 2% FBS and 0.1% sodium azide (FACS buffer; Sigma Aldrich) and stained with ALCAM-PE for an hour in the dark along with matched isotype controls. Approximately 100,0000 events per tube were captured using a Gallios TM flow cytometer (Beckman Coulter Inc., Brea, CA) or BD Accuri TM C6 (Becton Dickinson, Franklin Lakes, NJ) and data analysed by Kaluza software (Beckman Coulter Inc.) or FlowJo data analysis software (Flowjo LLC, Ashland, OR). Western blotting. Conditioned and non-conditioned endothelial cells (1 × 10 6 ) were lysed with RIPA lysis and extraction buffer (ThermoFisher Scientific) per © 2018 Springer Nature Limited. All rights reserved.
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Article reSeArcH manufacturer's recommendations and 10 μg each of protein extract was separated by SDS-PAGE, blotted onto PVDF membranes (GE Healthcare, Buckinghamshire, UK) and probed with primary antibodies against ALCAM (1:1,000) and β-actin (1:1,000) at 4 °C overnight. Following incubation with HRP-conjugated secondary anti-mouse (1:25,000) and anti-rabbit antibody (1:5,000), respectively, the blots were developed with ECL prime western blotting detection reagents (GE Healthcare, Chicago, IL, USA). Analysis was done using Image J (NIH) and ALCAM expression was normalized to β-actin. HS design, synthesis and production of HS T cells. Minimal binding to ALCAM was mapped in silico to domain 3 (D3) of native CD6 and the adjacent stalk (ST). Using Clone Manager (Sci-Ed Software, Cary, NC), the HS prototype molecule was designed as a leader sequence followed by an exodomain formed of domain 3 plus the stalk, followed by an IgG1 hinge, connected to CD6 transmembrane and a CD6 endodomain, formed of the full-length CD6 signalling domain (amino acids 30-400, NC_000011.10 (60971641..61020377)). Subsequently, multimers of the prototype (a trimer (3HS) and a pentamer (5HS)) were generated using multiples of the exodomain. Furthermore, to study the signalling domain function, truncated versions (HS∆, 3HS∆ and 5HS∆) were designed with a stop codon placed after 21 amino acids proximal to the transmembrane domain. Expression-optimized DNA sequences with exodomain wobbled in multimers were synthesized by GeneArt Inc. using oligonucleotides, and cloned into the Gateway entry vector pDONR221. Then each HS construct transgene was cloned in the correct frame into an SFG retroviral vector and sequences were verified. For the in vivo bioluminescence tracking, all HS sequences were followed by a 2A sequence and a GFP and firefly luciferase fusion transgene.
To produce retroviral supernatant, 293T cells were co-transfected with SFG retroviral vector, Peq-Pam-e plasmid encoding the sequence for MoMLV gag-pol, and plasmid pME-VSVG containing the sequence for VSV-G, using GeneJuice transfection reagent (EMD Biosciences, San Diego, CA). Retroviral supernatants were collected 48 and 72 h later and cryopreserved. OKT3/CD28-activated T cells were transduced with retroviral vectors as described 44 . In brief, peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Greiner Bio-One, Monroe, NC) Ficoll gradient centrifugation. 5 × 10 5 PBMCs per well in a 24-well plate were activated with OKT3 (OrthoBiotech, Raritan, NJ) and CD28 monoclonal antibodies (BD Biosciences, Palo Alto, CA) at a final concentration of 1 μg/ml.
For transduction, a non-tissue culture treated 24-well plate was pre-coated with a recombinant fibronectin fragment (Retronectin; Takara Bio USA, Madison, WI). Wells were washed with PBS and incubated twice for 30 min with the retrovirus supernatant. Subsequently, 2 × 10 5 T cells per well were transduced with retrovirus in the presence of IL-7 at 10 ng/ml and IL-15 at 5 ng/ml. After 48-72 h cells were removed and expanded in G-rex (Wilson Wolf, St Paul, MN) in T cell medium supplemented with IL-7 at 10 ng/ml and IL-15 at 5 ng/ml for 10-15 days before use.
Transduction efficiencies were assessed with flow cytometry using mouse anti-human D3 monoclonal antibody followed by goat anti-mouse Alexa-fluor 488 conjugate, or human ALCAM-Fc followed by a APC-conjugated goat anti-human Fc. Secondary only controls were incorporated and for all transductions percentage was normalized in comparison to native expression of CD6 on non-transduced (NT) control T cells.
HER2-CAR HS T cells used in the anti-tumour in vivo experiment were generated by co-transduction with FRP5 HER2-specific scFv 34,44 and the 5HS construct. Surface expression was detected with flow cytometry using goat anti-mouse Fab fragment specific antibody conjugated with DyLight 488 and HS mAb followed by goat anti-mouse AF 488. Reverse transcriptase polymerase chain reaction (RT-PCR). Using RNeasy extraction Kit (Qiagen), total RNA was extracted from 1 × 10 6 T cells 8 days after electroporation with control Cas9 only or with gRNA. 4 mg of pre-treated RNA with an RNase-free DNase and was used for cDNA synthesis by using the SuperScript III First-Strand Synthesis System (LifeTechnologies). Aliquots of the RT product were used for regular RT-PCR amplification for ALCAM and GAPDH as positive control. The reaction was carried out in a total volume of 20 μl containing 3 μl reverse-transcribed cDNA, 1 unit of Q5 high fidelity Taq polymerase (biolab), and 20 μM of each primer. For ALCAM cDNA, the forward primer, 5′-GTCTGGGCAATAGTGACT CC-3′ and reverse primer 5′-AACCATTGCAAGTGGAAA CC-3 were used. For the control housekeeping gene, GAPDH, the forward primer 5′-TGCACCACCAACTGCTTAGC-3′ and reverse primer 5′-GGCATGGACTGTGGTCATGAG-3′ were used. The resulting gene amplicons were analysed by agarose gel electrophoresis; ALCAM at 490 bp and GAPDP at 660 bp. Flow cytometry. T cell phenotype, exhaustion and proliferation. For phenotype analysis of the transmigrating T cells, 2 × 10 5 T cells, all HS T cell groups and the control T cells were stained with anti-human CCR7-PE-Cy7, and anti-human CD45RO-PE for 60 min at room temperature. Similarly, for exhaustion analysis, 2 × 10 5 T cells were collected from the bottom chamber after transmigration and washed with PBS then incubated with LAG3, TIM3 and PD-1 antibodies.
Versacomp antibody capture beads (Beckman Coulter, Bria, CA) were stained with the same antibodies to allow accurate compensation. For proliferation analysis, 2 × 10 5 T cells were collected before and after transmigration, and cells were washed and labelled with eFluor 670 diluted to 10 μM and incubated for 25 min at 37 °C in a water bath in the dark before the assay, according to the manufacturer's guidelines. Proliferation analysis and proliferation index comparison were done using FlowJo software. T cell signalling. For pZap70 and talin detection, 2.5 × 10 5 T cells, all HS T cells versus control T cells, were fixed and permeabilized using 4% PFA and 0.02% tween-20 then stained with anti-human pZap70-FITC and mouse monoclonal talin followed by anti-rabbit Alexa fluor 488. For LFA-1 open confirmation surface staining, 2.5 × 10 5 T cells were collected before and after transmigration and stained for LFA-1 specific extended confirmation using biotin labelled KIM127 (recognizes the extended integrin β-chain) followed by a secondary streptavidin-FITC antibody. More than 100,000 events were acquired using Accuri C6 (Becton Dickinson, Franklin Lakes, NJ). FlowJo data analysis software (FLOWJO, LLC, Ashland) was used for all flow cytometric analyses. Confocal microscopy. SLP-76. 50,000 GFP-tagged HS cells and ΔHS cells were collected and then seeded for 2 h over a glass chamber slide (Thermo Fisher Scientific) pre-coated overnight with 1 μg ALCAM, then fixed and permeabilized with Fixperm solution quenched with ammonium chloride, then incubated in blocking solution (PBS containing 0.01% Triton X-100 with 1% BSA). Finally, cells were immunolabelled with anti-phospho-SLP-76 (pTyr128) followed by antimouse Alexa 647. Clustering images of SLP76 at the HS-ALCAM interface were captured using a Zeiss Axio-Observer Z1 confocal microscope equipped with a Yokogawa CSU10 spinning disc, a Zeiss 63×/1.43 NA objective, and a Hamamatsu Orca-AG camera. Single 0.1μm z-slices with SLP-76 puncta at the eGFP-Gexpressing T cell surface were detected and compared to ΔHS cells. Talin-LFA-1-ICAM1 colocalization experiments. The endothelium-HS T cell interface was imaged using confocal microscopy. HS cells and control T cells were seeded over an HBMEC monolayer, pre-stimulated with TGFβ (0.1 μg/ml) for 4 h to ensure ALCAM expression, and incubated for 2 h at 37 °C to allow conjugate interactions. Conjugates between HS cells and HBMECs were then fixed and permeabilized with 4% paraformaldehyde and 0.02% saponin (Tween), blocked with PBS containing 0.01% Triton X-100 with 1% BSA and stained for LFA-1 open conformation, ICAM1, and talin. Primary antibodies were subsequently detected by anti-mouse AF 647, AF 488 secondary antibodies and anti-rabbit Alexa fluor pacific blue, respectively. An extra blocking step was performed between the two anti-mouse human antibody staining steps to eliminate background staining. HS cell-HBMEC conjugates were imaged as 0.2-μm Z-steps to cover the entire volume of the podosynapse, determined individually for each conjugate using a Zeiss Axio-Observer Z1 confocal microscope equipped with a Yokogawa CSU10 spinning disc, a Zeiss 63×/1.43 NA objective, and a Hamamatsu Orca-AG camera. Images were analysed with Volocity software (PerkinElmer, Waltham, MA). Cluster density of LFA-1, talin, ICAM1 and actin at the interface were calculated using the formula (volume × MFI) for an equal number of 1 × 1 × 1-μm voxels selected to cover the interface. Elisa of TGFβ and IL-6 in GBM supernatant. IL-6 and TGFβ were quantified using Elisa kits (ab46027) and (ab100647) according to the manufacturer's instructions (on three different samples of GBM supernatant collected 48 h after culture in DMEM without serum). Cytotoxicity assay. Cytotoxicity assays were performed as previously described 20 .
In brief, to test safety against ALCAM-positive endothelium, U87-GBM and HBMECs were used as targets, and to test fratricide effect, THP1, autologous NT T cells and autologous PBMCs were used. In all experiments: 1 × 10 6 target T cells labelled with 0.1 mCi (3.7MBq) 51 Cr at effector to target (E:T) ratios of 40:1, 20:1, 10:1 and 5:1. T cells incubated in complete medium alone or in 1% Triton X-100 were used to determine spontaneous and maximum 51 Cr release, respectively. After 4 h, cells were centrifuged; supernatants collected and radioactivity measured in a gamma counter (Cobra Quantum; PerkinElmer; Wellesley, MA). The mean percentage of specific lysis of triplicate wells was calculated according to the following formula: [test release − spontaneous release]/[maximal release − spontaneous release] × 100. Orthotopic GBM and MB xenogeneic SCID mouse model. Tumour establishment.
All animal experiments were conducted on a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee and all experiments complied with all relevant ethical regulations. Recipient ICR-SCID mice (C.B-Igh-1 b /IcrTac-Prkdc scid ) were purchased from Taconic (Hudson, NY, USA). Male and female 9-to 11-week-old mice were anaesthetized with isofluorane (Abbot Laboratories, UK) followed by an intraperitoneal injection of 225-240 mg/kg xylazine solution and then maintained on isoflurane by inhalation throughout the procedure. After removing hair from the head region, the mice were immobilized in a Cunningham Mouse/Neonatal Rat Adaptor (Stoelting, Wood Dale, IL, USA) stereotactic apparatus fitted into an E15600 Laboratory Standard Stereotaxic © 2018 Springer Nature Limited. All rights reserved.
Article reSeArcH Instrument (Stoelting, Wood Dale, IL, USA), and surgery area scrubbed with 1% povidone-iodine. A 10-mm skin incision was made along the midline. The tip of a 31G ½-inch needle mounted on a Hamilton syringe (Hamilton, Reno, NV, USA) served as the reference point. A 1-mm burr-hole was drilled into the skull 34,44 . HS T cell homing experiments. For the homing experiment, 5 × 10 4 unlabelled U87-GBM or DAOY-MB cells in 2.5 μl were injected orthotopically over 5 min. After 10 days of engraftment (based on previous experience xenograft will be vascularized 45,46 ), 10 7 T cells tagged with a GFP Firefly Luciferin fusion gene (eGFP-FFLuc) were injected intravenously through the tail vein. Groups of 15 mice received HS T cells and 10 mice received control NT T cells.
Homing of T cells to brain tumours was assessed by bioluminescence tracking in the brains of the animals using the IVIS system (Perkin Elmer, Akron, OH, USA) after intraperitoneal injection of 300 mg d-luciferin (Perkin Elmer). Mice under isofluorane anaesthesia were imaged individually at the highest sensitivity (level A) for 5 min each at hours 6, 24 and 48, and on days 3, 6 and 8 after T cell administration. Photon emission was quantified using the Living Image software (Perkin Elmer, Akron, OH, USA). A pseudo-colour image representing light intensity (blue: least intense, red: most intense) was generated and superimposed over the grayscale reference image. The regions of signal in the brain were obtained and compared between all test animals (n = 15 per group).
In order to assess specific homing and T cell infiltration to GBM xenografts, in a separate experiment, mice (n = 5) were euthanized after 24 h and the frontal right lobe containing the tumour was minced and TILs were enriched using a Percoll gradient. Then cells were stained using CD45-PerCp, CHS-APC and mouse anti-human HS mAb followed by anti-mouse AF 647 and analysed using flow cytometry gating concentrically on CD45, CHS and HS positivity. The percentage of TILs was compared between various HS T cell groups and control T cells.
To evaluate the specificity of tumour area homing, random infiltration was evaluated after mincing the left lobe distal from the tumour explants; TILs were isolated and assessed following the method described earlier. CAR HS T cell efficacy experiments. 5 × 10 4 eGFP-FFLuc-labelled U87-GBM cells in 2.5 μl were injected orthotopically over 5 min. Three groups of mice were randomized to receive HER2-CAR HS T cells (10 mice per group), HER2-CAR T cells (10 mice per group), NT T cells (5 mice per group) and tumour-only (3 mice per group) at day 6 and 11 days of engraftment through the tail vein. To evaluate the antitumour activity of T cells, tumour sizes were monitored by BLI. Mice were imaged twice weekly for 1 min using the IVIS system (IVIS, Xenogen Corp., Alameda, CA) under isofluorane anaesthesia and 100 μ μg d-luciferin (Xenogen, Alameda, CA) was injected intraperitoneally. Images were acquired and quantified as described earlier. In order to assess the homing of HER2-CAR HS cells, three mice that received HER2-CAR HS T cells or HER2-CAR T cells only in a separate experiment were euthanized, lobes containing the tumour area were minced and TILs were assessed as described above.
Mice were regularly examined for neurological deficits, weight loss, signs of stress, and a BLI signal >10 8 , and euthanized according to pre-set criteria according to the Baylor College of Medicine's Center for Comparative Medicine's guidelines. In none of the experiments were these criteria not fulfilled. Safety evaluation. The brain, heart, liver, spleen, lungs, stomach, intestine, testicles and kidneys were promptly collected after the mice used in the homing experiments (n = 5) were killed and fixed in a 10% formalin solution. Then, the organs were embedded in paraffin, sectioned, and processed for H&E staining and pathologically assessed for histological abnormality or toxicity by a neuropathologist. IHC was carried out on 3 μm brain tumour tissues of different groups (n = 3 per group) and probed using rabbit anti-human CD3 (Abcam). Statistical analysis. Data were summarized using descriptive statistics. Comparisons between groups were carried out using one-way ANOVA or t-test. P values were adjusted for multiple comparisons using Tukey's test and Dunnet's test when appropriate. The Kaplan-Meier method was used to estimate survival curves and the log-rank test was used to compare the curves. GraphPad Prism 7 software (La Jolla, CA) was used for statistical analysis. The sample size for the animal experiments was calculated on the basis of the primary hypothesis and models derived from pilot studies. Animals were randomized between groups and the operator was blinded to the agents tested. A P value of less than 0.05 was considered significant. 
Article reSeArcH Extended Data Fig. 3 | In silico design of the prototype and derivative HS molecules, their forced expression and detection on T cells, and studies of their in vitro dynamic interactions with endothelial cells under shear stress. a, The potential interaction between ALCAM V1 (grey ribbon) and CD6 from computational docking. D1 of CD6 is coloured blue, D2 green and D3 orange. b, Details of the potential interaction interface between ALCAM V1 (grey ribbon) and CD6 D3 (orange ribbon). A rendering of the electrostatic surface of ALCAM V1 (grey ribbon) with the D3 domain of CD6 (orange ribbon) in the same orientation. Potential interacting residues are highlighted in the models and in a diagram generated from PDBe PISA and PDBSum (c). A small region of positively charged residues in ALCAM V1 appears to interact with a negatively charged patch of residues on CD6 D3. d, Structure of the prototype HS molecule. e, HS multimers 3HS and 5HS. f, HS molecules with non-signalling endodomains, HSΔ, 3HSΔ and 5HSΔ. g, Strategy used for surface detection of the HS exodomain using a D3-specific antibody and specific binding of the HS exodomain to soluble ALCAM. h, Flow cytometry confirming HS surface expression (using D3 monoclonal antibody) on T cells. i, Design of the HS-ALCAM PLA experiment. j, Digital rendition of PLA using ImageTool. The ALCAM probe (-) binds to the D3 probe (+) to trigger the PCR generating the red fluorescent signal that is quantified as total signal per region (TSR) in Fig. 2f. k, l for CD45RO and CCR7 to assess their centrality (b), expression of the exhaustion markers PD-1 (black), TIM-3 (red) and LAG3 (orange) (before transmigration is shown in grey) (c), and proliferative capacity before (red) and after (blue) transmigration, using efLuor 670 (d).
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Article reSeArcH Extended Data Fig. 9 | Analysis of TILs isolated from tumour xenografts and normal brain for HER2-CAR HS T cells. a, Flow cytometry of TILs isolated from orthotopic tumour xenografts 24 h after intravenous injection of HS T cell products, HER2-CAR T cells and NT control T cells. Xenografts were micro-dissected and TILs were isolated and enriched on a percoll/ficoll gradient. Cells were gated on D3 + subset inside a gate of D3 + CD45 + . A subset of HER2-CAR inside a gate of CD3 + CD45 + D3 + was used to detect HER2-CAR HS T cells specifically. n = 5 mice per group, representative data shown. b, Flow cytometry following the same gating strategy indicating the absence of HS T cells in the contralateral lobe to the tumour xenograft; data representative of three mice.
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